Abstracts - faqs.org

Abstracts

Business

Search abstracts:
Abstracts » Business

The CREATE Act: Increasing costs associated with the biotech industry?

Article Abstract:

The CREATE Act, which became effective on September 15, 2005 is intended to promote collaboration among industry actors and ease innovation, decrease costs, encourage commercialization of patentable products in the biotech sector and ultimately promote dissemination of biotechnological advances to improve health. The Act might actually increase the costs of research, development and commercialization and hence is important to have close monitoring of the impact of the CREATE ACT as changes in the structure and financing of biotech are made response to the CREATE ACT.

Author: Mills, Ann E., Chen, Donna T., Gillon, John J., Jr., Tereskerz, Patti M.
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
Economic aspects

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


The gatekeepers of hES cell products

Article Abstract:

The exclusive ownership among the Wisconsin Alumni Research Foundation (WARF), Geron, and the US National Institutes of Health (NIH) in the United States to control the access to human embryonic stem (hES) cells has intensified the debate over the impact of the US patent system on biomedical innovation and access to the market for hES cell products. Access to hES cells is mediated by a political, legal, and economic infrastructure assembled on the foundation of two US patents.

Author: Rabin, Sander
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2005
Science & research, Research, Access control, Embryonic stem cells, Wisconsin Alumni Research Foundation

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


The human use of humanoid beings: Chimeras and patent law

Article Abstract:

The United States Patent and Trademark Office (USPTO) policy has ruled on whether a patent might issue on a self-aware, human-nonhuman chimera, but Congress is yet to legislate a dividing line between human and non-human patentable subject matter. The proposals that have provided guidelines to ban humanization of animals without imposing undue burdens on the biotech industry are discussed.

Author: Rabin, Sander
Publisher: Nature Publishing Co.
Publication Name: Nature Biotechnology
Subject: Business
ISSN: 1087-0156
Year: 2006
United States. Patent and Trademark Office, Chimeras (Organisms)

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: United States, Biotechnology industry, Biotechnology industries, Intellectual property
Similar abstracts:
  • Abstracts: The effect of uncertainty and asset co-specialization on governance in biotechnology alliances
  • Abstracts: Una Ryan. Executive compensation at private biotech companies: Beyond hearsay. Alexis Borisy
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.
Some parts © 2025 Advameg, Inc.